Mota, Jose Mauricio http://orcid.org/0000-0001-9510-6956
Armstrong, Andrew J. http://orcid.org/0000-0001-7012-1754
Larson, Steven M.
Fox, Josef J.
Morris, Michael J. http://orcid.org/0000-0002-9454-0096
Article History
Received: 8 February 2019
Revised: 11 March 2019
Accepted: 24 March 2019
First Online: 29 April 2019
Compliance with ethical standards
:
: We declare the following conflicts of interest. Dr. Mota: none relevant to this manuscript. Dr. Armstrong: none relevant to this manuscript. Dr. Larson reports receiving commercial research grants from Genentech, Inc., WILEX AG, Telix Pharmaceuticals Limited, and Regeneron Pharmaceuticals, Inc.; holding ownership interest/equity in Voreyda Theranostics Inc. and Elucida Oncology Inc., and holding stock in ImaginAb, Inc. SML is the inventor and owner of issued patents both currently unlicensed and licensed by MSK to Samus Therapeutics, Inc. and Elucida Oncology, Inc. SML is or has served as a consultant to Cynvec LLC, Eli Lilly & Co., Prescient Therapeutics Limited, Advanced Innovative Partners, LLC, Gerson Lehrman Group, Progenics Pharmaceuticals, Inc., and Janssen Pharmaceuticals, Inc. Dr. Fox: None relevant to this manuscript. Dr. Morris reports unpaid consultant for Bayer, Endocyte, Progenics, Janssen; paid consultant for Oric Pharmaceuticals and Advance Acclerator Applications; research funding: Genentech/Roch, Endocyte, Bayer, Progenics, Astellas, Corcept.